Enzyme Replacement Therapy for Metabolic Disease

Rare Metabolic Disorders

$10.1 billion global ERT market in 2024

Enzyme replacement therapy provides a functional copy of a missing or defective enzyme to patients with inherited metabolic disorders. Peptide-based innovations are now solving the two biggest problems in ERT: getting enzymes inside cells and across the blood-brain barrier.

Straits Research, Enzyme Replacement Therapy Market, 2025

Straits Research, Enzyme Replacement Therapy Market, 2025

View as image

Inborn errors of metabolism are genetic conditions where a single enzyme is missing or non-functional, causing toxic substrates to accumulate in cells. The concept behind enzyme replacement therapy (ERT) is straightforward: provide the patient with a working copy of the enzyme they cannot make. The first successful ERT, imiglucerase for Gaucher disease, reached the market in 1994 and demonstrated that intravenous infusion of recombinant enzymes could reverse organ damage caused by decades of substrate accumulation. Since then, ERTs have been approved for Fabry disease, Pompe disease, mucopolysaccharidosis types I, II, IV, VI, and VII, and acid sphingomyelinase deficiency.

The pillar article on setmelanotide and rare genetic obesity syndromes covers how peptide therapeutics treat monogenic metabolic conditions through receptor agonism. ERT takes a different approach: replacing the enzyme itself rather than correcting a signaling defect. Where setmelanotide activates a functioning MC4R receptor pathway to restore appetite regulation, ERT provides the actual missing protein to restore a broken metabolic process.

How ERT Works: Replacing What the Body Cannot Make

Inborn errors of metabolism arise from mutations in genes encoding specific enzymes. In lysosomal storage diseases (LSDs), the affected enzymes normally reside inside lysosomes, the cellular compartments responsible for breaking down complex molecules. Without the enzyme, substrates accumulate inside lysosomes, eventually damaging cells and organs.

ERT delivers a recombinant version of the missing enzyme intravenously. The enzyme is manufactured in Chinese hamster ovary (CHO) cells, human fibroblasts, or plant cells, then modified with mannose-6-phosphate (M6P) residues that target it to the lysosome. After infusion, the enzyme circulates in the bloodstream, is taken up by cells through M6P receptors on cell surfaces, and is trafficked to lysosomes where it breaks down the accumulated substrate.

The process has clear limitations. The recombinant enzyme is a large protein (40-120 kDa) that cannot cross cell membranes on its own. It depends entirely on receptor-mediated endocytosis for uptake. Tissues with low M6P receptor density receive less enzyme. The blood-brain barrier blocks entry into the central nervous system. And the immune system can produce antibodies against the infused enzyme, reducing its effectiveness over time.

The Approved ERT Landscape

Lysosomal Storage Diseases

Six LSDs now have FDA-approved ERTs:

Gaucher disease (glucocerebrosidase deficiency): Imiglucerase (Cerezyme, 1994), velaglucerase alfa (VPRIV, 2010), and taliglucerase alfa (Elelyso, 2012) all replace the missing GCase enzyme. Gaucher type 1, the most common form, responds well because the target cells (macrophages) are accessible in the bloodstream and have high M6P receptor density. ERT reverses hepatosplenomegaly, improves blood counts, and reduces bone disease.

Fabry disease (alpha-galactosidase A deficiency): Agalsidase alfa (Replagal), agalsidase beta (Fabrazyme, 2003), and pegunigalsidase alfa (Elfabrio, 2023) target the accumulated globotriaosylceramide (Gb3) in vascular endothelium, kidneys, and heart. Kukacka et al. (2018) mapped antibody epitopes on recombinant alpha-galactosidase A, work that helps predict and manage the immune responses that reduce ERT efficacy in roughly 40-70% of male Fabry patients.^[1]

Pompe disease (acid alpha-glucosidase deficiency): Alglucosidase alfa (Lumizyme/Myozyme, 2006) and the newer combination of cipaglucosidase alfa with miglustat (Pombiliti/Opfolda, 2023) replace the enzyme responsible for glycogen breakdown in lysosomes. Without treatment, infantile-onset Pompe disease is fatal within the first year.

Mucopolysaccharidoses: Laronidase (Aldurazyme, 2003) for MPS I, idursulfase (Elaprase, 2006) for MPS II, galsulfase (Naglazyme, 2005) for MPS VI, elosulfase alfa (Vimizim, 2014) for MPS IVA, and vestronidase alfa (Mepsevii, 2017) for MPS VII each target different enzymes in the glycosaminoglycan degradation pathway.

Beyond Lysosomes

ERT extends beyond LSDs. Pegvaliase (Palynziq, 2018) treats phenylketonuria (PKU) through a different mechanism: it provides an alternative enzyme (phenylalanine ammonia lyase) that breaks down phenylalanine through a pathway that bypasses the defective phenylalanine hydroxylase. In phase III trials, 60.7% of patients achieved blood phenylalanine levels below the recommended threshold of 360 umol/L at 24 months.

Olipudase alfa (Xenpozyme, 2022) treats acid sphingomyelinase deficiency, and sebelipase alfa (Kanuma, 2015) treats lysosomal acid lipase deficiency. Cerliponase alfa (Brineura, 2017) is administered directly into the cerebrospinal fluid for neuronal ceroid lipofuscinosis type 2, the only approved intrathecal ERT.

The Peptide Innovation Layer

Peptide-Guided Lysosomal Targeting

The standard M6P-dependent targeting pathway has limitations: not all cells express high levels of M6P receptors, the glycosylation required for M6P tagging is expensive and variable, and some recombinant enzymes have suboptimal M6P modification. Peptide-based alternatives offer new routes to the lysosome.

Iwasaki et al. (2020) developed a polylysine-polyhistidine fusion peptide (K10H16) that delivers functional enzymes to intracellular lysosomes through electrostatic complexation. The peptide binds the enzyme cargo through charge interactions, mediates cellular uptake, and releases the enzyme in the acidic lysosomal environment. In cells derived from lysosomal storage disease patients, the K10H16-enzyme complex restored normal cell growth without requiring M6P modification.^[2]

Hayashi et al. (2019) took an even more ambitious approach with organelle replacement therapy. Using a stearyl-polyhistidine peptide, they packaged entire functional lysosomes for delivery into cells with defective lysosomal function. Rather than replacing a single enzyme, the approach replaces the entire organelle.^[3]

Cell-Penetrating Peptides for Enzyme Delivery

The largest barrier to ERT efficacy is getting enzymes across cell membranes and into the correct intracellular compartment. Cell-penetrating peptides (CPPs) solve the membrane crossing problem.

Yu et al. (2021) demonstrated efficient intracellular delivery of proteins using a multifunctional chimeric peptide that combined cell penetration, endosomal escape, and organelle targeting in a single molecule. In animal models, the system reduced inflammation and liver failure, demonstrating that CPP-enzyme complexes can achieve therapeutic effects in vivo.^[4]

Schneider et al. (2019) developed targeted subcellular protein delivery using cleavable cyclic cell-penetrating peptides. The cyclic structure improved protease resistance during transit, while the cleavable linker released the protein cargo once inside the target compartment.^[5]

Setegne et al. (2025) engineered cell-specific protein delivery vehicles for erythroid lineage cells, testing multiple approaches including cell-penetrating peptides, bacterial toxin-based systems, and injection systems. The study revealed that delivery efficiency varied dramatically between platforms, and targeting cell surface receptors improved some vehicles but not others.^[6]

PEGylation: Extending Enzyme Half-Life

Recombinant enzymes are rapidly cleared from the bloodstream by the immune system and kidneys. PEGylation, attaching polyethylene glycol chains to the enzyme, extends circulation time by shielding the protein from immune recognition and reducing renal clearance.

Kumar et al. (2020) reviewed how PEGylation and cell-penetrating peptides address complementary problems in protein therapeutics. PEGylation extends systemic half-life (addressing the stability problem), while CPPs enhance intracellular uptake (addressing the delivery problem). The combination of both strategies represents a potential next generation of ERT design.^[7]

Pegvaliase exemplifies this approach. The PEG coating on the PAL enzyme extends its half-life sufficiently for subcutaneous injection rather than intravenous infusion, improving patient quality of life. The trade-off is immunogenicity: 21.6% of patients in clinical practice experienced anaphylactic reactions, compared to 10% in controlled trials.

The Blood-Brain Barrier Problem

Many inborn errors of metabolism cause their most devastating damage in the brain. MPS types I, II, and III, Gaucher disease types 2 and 3, Pompe disease, and multiple other LSDs have neurological components that current intravenous ERT cannot address. The blood-brain barrier (BBB) blocks passage of the large enzyme proteins.

Nithya et al. (2025) reviewed protein-based therapeutic delivery approaches targeting the BBB, including peptide-mediated transcytosis. Receptor-mediated transport using transferrin receptor-targeting peptides, LRP1-binding peptides (such as angiopep-2), and insulin receptor-targeting sequences can shuttle protein cargo across the BBB endothelium.^[8]

Cerliponase alfa (Brineura) bypasses the BBB entirely through intrathecal administration directly into the cerebrospinal fluid. This works for CLN2 disease but requires neurosurgical implantation of an access device and biweekly infusions, limiting its applicability to other conditions.

The peptide gene therapy approach offers a different solution: rather than repeatedly delivering the enzyme, deliver the gene encoding the enzyme using peptide-based vectors. This could provide sustained enzyme production within the CNS without repeated infusions.

Limitations of Current ERT

Immune responses. The infused enzyme is a foreign protein. Between 40-70% of Fabry disease patients and a significant proportion of Pompe disease patients develop anti-drug antibodies (ADAs) that neutralize the enzyme, accelerate its clearance, or cause infusion reactions. Immune tolerance induction protocols exist but are complex and not always effective.

Tissue distribution. Intravenous enzymes reach the liver and spleen efficiently (high M6P receptor density, fenestrated endothelium) but poorly penetrate muscle, bone, cartilage, and the central nervous system. This is why Pompe disease patients on ERT still experience progressive muscle weakness and why MPS patients develop skeletal deformities despite treatment.

Cost. ERT for lysosomal storage diseases costs $100,000-$750,000 per patient per year, making them among the most expensive therapies in medicine. The high cost reflects small patient populations, complex manufacturing, and the need for lifelong treatment.

Frequency. Most ERTs require intravenous infusions every 1-2 weeks for life, imposing substantial burden on patients and healthcare systems. Subcutaneous formulations (pegvaliase) and longer-acting formulations are being developed but remain limited.

Brain inaccessibility. With the exception of intrathecal cerliponase alfa, no approved ERT reaches the CNS at therapeutic concentrations. This means the neurological component of many metabolic diseases progresses despite systemic ERT, representing the single largest unmet need in the field.

ERT in the Context of Peptide Therapeutics for Rare Disease

ERT represents one approach within a broader landscape of peptide therapeutics for rare metabolic disorders. While ERT replaces a missing enzyme directly, other peptide-based strategies work through different mechanisms.

POMC, the precursor peptide that generates alpha-MSH and other melanocortins, illustrates the connection between enzyme processing and peptide signaling. POMC deficiency is itself an inborn error of metabolism where the problem is not a missing metabolic enzyme but a missing peptide precursor. Setmelanotide treats POMC deficiency by replacing the downstream signal rather than the precursor itself.

AgRP, which antagonizes MC4R signaling, demonstrates how peptide imbalances in metabolic circuits can produce disease phenotypes comparable to enzyme deficiencies. Understanding the broader melanocortin pathway reveals why some metabolic disorders respond to ERT (substrate accumulation diseases) while others respond to peptide agonists (signaling deficiency diseases).

The distinction matters for treatment design. Substrate accumulation diseases require enzyme replacement at doses sufficient to clear the accumulated material. Signaling deficiency diseases require peptide agonists at doses sufficient to activate the target receptor. Both are protein/peptide therapeutics for inborn errors of metabolism, but the pharmacological logic is fundamentally different.

The Bottom Line

Enzyme replacement therapy provides functional copies of missing enzymes to patients with inherited metabolic disorders, with 14+ approved products treating lysosomal storage diseases and other inborn errors of metabolism. Peptide innovations are addressing ERT's two critical limitations: cell-penetrating peptides and lysosomal-targeting peptides improve intracellular enzyme delivery, while BBB-crossing peptides and intrathecal delivery attempt to reach the CNS. PEGylation extends enzyme circulation time. Gene therapy may eventually replace repeated infusions with one-time corrections. Current ERTs transform fatal diseases into manageable conditions but remain limited by immune responses, tissue distribution, CNS inaccessibility, and extreme cost.

Frequently Asked Questions

What is enzyme replacement therapy and how does it work?

Enzyme replacement therapy delivers a recombinant version of a missing or defective enzyme to patients with inherited metabolic disorders through intravenous infusion. The enzyme is tagged with mannose-6-phosphate residues that direct it to lysosomes inside cells, where it breaks down accumulated substrates. Fourteen ERT products are currently approved for conditions including Gaucher disease, Fabry disease, Pompe disease, and multiple mucopolysaccharidoses.

What diseases are treated with enzyme replacement therapy?

ERT is approved for at least 10 inherited metabolic diseases: Gaucher disease (types 1 and 3), Fabry disease, Pompe disease, MPS types I, II, IVA, VI, and VII, acid sphingomyelinase deficiency, lysosomal acid lipase deficiency, CLN2 disease (intrathecal), and phenylketonuria (enzyme substitution with pegvaliase). Most are lysosomal storage diseases affecting 1 in 5,000 to 1 in 100,000 births.

How much does enzyme replacement therapy cost per year?

ERT for lysosomal storage diseases costs $100,000 to $750,000 per patient per year, making them among the most expensive therapeutics available. The high cost reflects small patient populations (often fewer than 10,000 patients worldwide per disease), complex recombinant protein manufacturing, and lifelong treatment requirements. The global ERT market was valued at $10.1 billion in 2024.

Can enzyme replacement therapy treat brain symptoms?

Most intravenous ERTs cannot cross the blood-brain barrier, leaving neurological symptoms of metabolic diseases untreated. The one exception is cerliponase alfa (Brineura), delivered directly into the cerebrospinal fluid for CLN2 disease. Peptide-based approaches using BBB-crossing sequences (angiopep-2, transferrin receptor-targeting peptides) are being developed to shuttle enzymes across the barrier, but none are yet approved.

What is pegvaliase and how is it different from other ERTs?

Pegvaliase (Palynziq) is a PEG-conjugated phenylalanine ammonia lyase enzyme approved for phenylketonuria (PKU) in 2018. Unlike lysosomal ERTs that replace the exact missing enzyme, pegvaliase provides an alternative enzyme from plants that breaks down phenylalanine through a different metabolic pathway. In clinical trials, 60.7% of patients achieved target phenylalanine levels at 24 months. It is administered subcutaneously rather than intravenously.

How do peptides improve enzyme replacement therapy?

Peptides address ERT's delivery limitations in three ways. Cell-penetrating peptides ferry enzymes across cell membranes into intracellular compartments. Lysosomal-targeting peptides like K10H16 deliver enzymes to lysosomes without requiring mannose-6-phosphate modification. Blood-brain barrier-crossing peptides shuttle protein cargo into the CNS. PEGylation (adding polymer chains) extends enzyme circulation time from hours to days.